Clinical Trials · NCT07583563

An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly

Phase
N/A
Recruitment status
Recruiting
Sponsor
Camurus AB
Enrollment
200
Start date
Jun 2026
Locations
5 sites, Germany
Primary endpoint
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
View Octreotide compound reference